Clearmind Medicine (CMND) details CMND-100 Phase I/IIa second cohort news

Rhea-AI Filing Summary

Clearmind Medicine Inc. furnished a Form 6-K to report that it issued a press release titled "Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100". The update indicates that enrollment of the second patient group in this early-stage, FDA-approved study of CMND-100 has been successfully completed. The first paragraph of the press release is also incorporated by reference into Clearmind’s existing registration statements on Forms F-3 and S-8.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on December 16, 2025, titled “Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100”.

The first paragraph of the press release attached to this Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: December 16, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine Inc. disclose in this Form 6-K (CMND)?

Clearmind Medicine Inc. disclosed that it issued a press release titled "Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100" and furnished that release as an exhibit.

What is the main update about CMND-100 mentioned for Clearmind Medicine (CMND)?

The main update is the successful completion of second cohort enrollment in an ongoing FDA-approved Phase I/IIa trial for Clearmind’s investigational product CMND-100.

How does this Form 6-K affect Clearmind Medicine’s registration statements (CMND)?

The first paragraph of the attached press release is incorporated by reference into Clearmind Medicine’s existing registration statements on Form F-3 and Form S-8, making that trial update part of those documents.

Which clinical trial phase is referenced for CMND-100 in Clearmind Medicine’s update (CMND)?

The update refers to an ongoing FDA-approved Phase I/IIa trial for CMND-100, and notes that enrollment of the second cohort in this study has been completed.

Does this Clearmind Medicine Form 6-K (CMND) focus on financial results or clinical progress?

This Form 6-K centers on clinical progress, specifically the successful completion of second cohort enrollment in the FDA-approved Phase I/IIa trial for CMND-100 and the inclusion of that update in existing registration statements.